<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2911200298
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Montas
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What MONTAS is</strong><br />Montas is a leukotriene receptor antagonist that blocks substances called leukotrienes.<br /><strong>How Montas works</strong><br />Leukotrienes cause narrowing and swelling of airways in the lungs and also cause allergy symptoms. By blocking leukotrienes, Montas improves asthma symptoms, helps control asthma and improves seasonal allergy symptoms (also known as hay fever or seasonal allergic rhinitis).<br /><strong>When Montas should be used</strong><br />Your doctor has prescribed Montas to treat asthma, preventing your asthma symptoms during the day and night.<br />&bull; Montas is used for the treatment of adults and adolescents 15 years of age and older who are not adequately controlled on their medication and need additional therapy.<br />&bull; Montas also helps prevent the narrowing of airways triggered by exercise.<br />&bull; In those asthmatic patients in whom MONTAS is indicated in asthma, MONTAS can also provide symptomatic relief of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of MONTAS may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis<br />Montas should only be reserved to treat allergic rhinitis in patients who are not treated effectively with or cannot tolerate other allergy medicine.<br />Your doctor will determine how MONTAS should be used depending on the symptoms and severity of your asthma.<br /><strong>What is asthma?</strong><br />Asthma is a long-term disease.<br />Asthma includes:<br />&bull; Difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.<br />&bull; Sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.<br />&bull; Swelling (inflammation) in the lining of the airways.<br />Symptoms of asthma include: Coughing, wheezing, and chest tightness<br /><strong>What are seasonal allergies?</strong><br />Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an allergic response often caused by airborne pollens from trees, grasses and weeds. The symptoms of seasonal allergies typically may include: stuffy, runny, itchy nose; sneezing; watery, swollen, red, itchy eyes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you have now or have had.</p><p><strong>&nbsp;</strong></p><p><strong>Do not take MONTAS</strong></p><p>If you are allergic (hypersensitive) to montelukast or any of the other ingredients of MONTAS (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Montas</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your asthma or breathing gets worse, tell your doctor immediately.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral Montas is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you. Always have your inhaled rescue medicine for asthma attacks with you.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that you or your child take all asthma medications prescribed by your doctor. Montas should not be substituted for other asthma medications your doctor has prescribed for you.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any patient on anti-asthma medicines should be aware that if you develop a combination of symptoms such as a flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your asthma worse.&nbsp;</p><p>&nbsp;</p><p>Patients should be aware that various Serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patient taking Montelukast.</p><p>&nbsp;</p><p>If you develop such symptoms while taking MONTAS, you should consult your doctor.</p><p>&nbsp;</p><p>Ask patients about any history of psychiatric illness prior to initiating treatment.</p><p>&nbsp;</p><p>Consider the risks and benefits of montelukast when deciding to prescribe or continue patients on the medicine.</p><p>&nbsp;</p><p>Monitor all patients treated with montelukast for neuropsychiatric symptoms. Events have occurred in patients with and without pre-existing psychiatric disease.</p><p>&nbsp;</p><p>Advise patients and parents/caregivers that the patient should stop taking montelukast and contact a health care professional immediately if changes inbehavior or new neuropsychiatric symptoms, suicidal thoughts or behavior occur.</p><p>&nbsp;</p><p>Most reported cases of neuropsychiatric events occurred during montelukasttreatment, but some occurred after discontinuation.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Do not give this medicine to children less than 15 years of age.</p><p>There are different form(s) of this medicine available for paediatric patients under 18 years of age based on age range.</p><p>&nbsp;</p><p><strong>Taking other medicines </strong></p><p>Some medicines may affect how MONTAS works, or MONTAS may affect how other medicines work.</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken other medicines, including those obtained without a prescription.</p><p>Tell your doctor if you are taking the following medicines before starting MONTAS:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenobarbital (used for treatment of epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used for treatment of epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used to treat tuberculosis and some other infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gemfibrozil (used for treatment of high lipid levels in plasma)</p><p>&nbsp;</p><p><strong>Taking MONTAS with food and drink </strong></p><p>Montas 10 mg film-coated tablet may be taken with or without food.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, askyour doctor or pharmacist for advice before taking MONTAS.</p><p><strong>&nbsp;</strong></p><p><em>Use in pregnancy </em></p><p>Your doctor will assess whether you can take MONTAS during this time.</p><p>&nbsp;</p><p><em>Use in breast-feeding </em></p><p>It is not known if Montas appears in breast milk. You should consult your doctor before taking Montas if you are breast-feeding or intend to breast-feed.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>MONTAS is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with MONTAS may affect some patients&rsquo; ability to drive or operate machinery.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of MONTAS</strong></p><p>MONTAS 10 mg film-coated tablets contain lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should take only one tablet of MONTAS once a day as prescribed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It should be taken even when you have no symptoms or have an acute asthma attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To be taken by mouth</p><p><strong>For adults 15 years of age and older:</strong></p><p>One 10 mg tablet to be taken daily in the evening. MONTAS 10 mg may be taken with or without food.</p><p>If you are taking MONTAS, be sure that you do not take any other products that contain the same active ingredient, montelukast.</p><p>&nbsp;</p><p><strong>If you take more MONTAS than you should </strong></p><p>Contact your doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p>&nbsp;</p><p><strong>If you forget to take MONTAS</strong></p><p>Try to take MONTAS as prescribed. However, if you miss a dose, just resume the usual schedule of one tablet once daily.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking MONTAS</strong></p><p>MONTAS can treat your asthma only if you continue to take it.</p><p>It is important to continue taking MONTAS for as long as your doctor prescribes. It will help control your asthma.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, MONTAS can cause side effects, although not everybody gets them.</p><p>In clinical studies with MONTAS 10 mg film-coated tablets, the <strong><em>most commonly</em></strong> reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 patients treated) thought to be related to MONTAS were:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>These were usually mild and occurred at a greater frequency in patients treated with MONTAS than placebo (a pill containing no medication).</p><p>&nbsp;</p><p>The frequency of possible side effects listed below is defined using the following convention:</p><p>Very common (affects at least 1 user in 10), Common (affects 1 to 10 users in 100) ,Uncommon (affects 1 to 10 users in 1,000), Rare (affects 1 to 10 users in 10,000), Very rare (affects less than 1 user in 10,000), Not known: frequency cannot be estimated from the available data</p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects </strong></p><p><strong>Talk with your doctor immediately </strong>if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment</p><p><strong>Uncommon</strong> (affects 1 to 10 users in 1,000)</p><p>&sect;&nbsp; Allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing</p><p>&sect;&nbsp; behaviour and mood related changes: agitation including aggressive behaviour or hostility, anxiousness,depression</p><p>&sect;&nbsp; seizure</p><p>&nbsp;</p><p><strong>Rare:</strong> the following may affect up to 1 in 1,000 people</p><p>&sect;&nbsp; increased bleeding tendency</p><p>&sect;&nbsp; tremor</p><p>&sect;&nbsp; palpitations</p><p>&nbsp;</p><p><strong>Very rare:</strong> the following may affect up to 1 in 10,000 people</p><p>&sect;&nbsp; combination of symptoms such as flu-like illness, pins and needles or numbness of arms andlegs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see section 2)</p><p>&sect;&nbsp; &nbsp;low blood platelet count</p><p>&sect;&nbsp; behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and<br />actions</p><p>&sect;&nbsp; swelling (inflammation) of the lungs</p><p>&sect;&nbsp; severe skin reactions (erythema multiforme) that may occur without warning</p><p>&sect;&nbsp; &nbsp;inflammation of the liver (hepatitis)</p><p>&nbsp;</p><p><strong>Other side effects while the medicine has been on the market</strong></p><p><strong>Very common:</strong> the following may affect more than 1 in 10 people</p><p>&sect;&nbsp; upper respiratory infection</p><p>&nbsp;</p><p><strong>Common:</strong> the following may affect up to 1 in 10 people</p><p>&sect;&nbsp; diarrhoea, nausea, vomiting</p><p>&sect;&nbsp; rash</p><p>&sect;&nbsp; fever</p><p>&sect;&nbsp; elevated liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon:</strong> the following may affect up to 1 in 100 people</p><p>&sect;&nbsp; behaviour and mood related changes: dream abnormalities, including nightmares, trouble<br />sleeping, sleepwalking, irritability, feeling anxious, restlessness</p><p>&sect;&nbsp; dizziness, drowsiness, pins and needles/numbness</p><p>&sect;&nbsp; nosebleed</p><p>&sect;&nbsp; dry mouth, indigestion</p><p>&sect;&nbsp; bruising, itching, hives</p><p>&sect;&nbsp; joint or muscle pain, muscle cramps</p><p>&sect;&nbsp; bedwetting in children</p><p>&sect;&nbsp; weakness/tiredness, feeling unwell, swelling</p><p>&nbsp;</p><p><strong>Rare:</strong> the following may affect up to 1 in 1,000 people</p><p>&sect;&nbsp; Behaviour and mood related changes: disturbance in attention, memory impairment,<br />uncontrolled muscle movements</p><p>&nbsp;</p><p><strong>Very rare:</strong> the following may affect up to 1 in 10,000 people</p><p>&sect;&nbsp; tender red lumps under the skin, most commonly on your shins (erythema nodosum)</p><p>&sect;&nbsp; Behaviour and mood related changes: obsessive-compulsive symptoms, dysphemia (stuttering).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiration date. This medicine expires at the end of the month shown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: montelukast. Each tablet contains montelukast sodium which corresponds to 10 mg of montelukast.</p><p>The other ingredients are: Lactose monohydrate, microcrystalline cellulose, Croscarmellose sodium, Ethanol, Hydroxypropylcellulose, Magnesium stearate, Opadry AMB TAN (80W27179) &amp; Purified water.</p><p>Opadry AMB TAN (80W27179) blend consisting of polyvinyl alcohol, Titanium dioxide (E171), Talc, Iron oxide yellow (&Epsilon;172), Lecithin, Xanthan gum, Iron Oxide red (&Epsilon;172) and Iron oxide black (&Epsilon;172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Montas 10mg film coated tablets are Beige, Round biconvex tablets with “MN 10” debossed on one side and plain on the other side.
Aluminium/Aluminium Laminate Foil (OPA/AL/PVC) blister pack of 28 tablets (4 × 7’s)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Oman Pharmaceutical Products Co. L.L.C.</strong></p><p>Plot No 101, Raysut Industrial Estate,</p><p>Salalah, Sultanate of Oman</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ماهو مونتاس </strong></p><p dir="RTL">&nbsp;مونتاس هو مثبط لمستقبلات الليكوتراين الذي يمنع مواد تسمى الليكوترينات.</p><p dir="RTL"><strong>كيف يعمل مونتاس</strong></p><p dir="RTL">الليكوترينات تسبب ضيق وتورم في الشعب الهوائية في الرئتين. بثبيط الليكوترينات ، مونتاس يحسن أعراض الربو ويساعد في السيطرة عليه ويحسن أعراض الحساسية الموسمية (المعروف أيضا باسم حمى القش أو حساسية الأنف الموسمية).</p><p dir="RTL"><strong>متى يجب أن تستخدم مونتاس</strong></p><p dir="RTL">طبيبك بوصف مونتاس لعلاج الربو، ومنع أعراض الربو الخاص بك خلال النهار والليل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم مونتاس لعلاج المرضى البالغين والمراهقين 15 سنة من العمر وكبار السن الذين لا يسيطر على حالتهم بشكل كاف مع علاجاتهم و يحتاجون الى علاج&nbsp; إضافي.&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مونتاس يساعد على منع تضييق الشعب الهوائية الناجم عن ممارسة الرياضة&nbsp;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;في المرضى المصابين بالربو وتم صرف مونتاس لهم ، يمكن أيضا أن يوفر لهم مونتاس تخفيف أعراض حساسية الأنف الموسمية في المرضى الذين تتراوح أعمارهم بين ٢ سنة وما فوق والتهاب الأنف التحسسي الدائم في المرضى الذين تتراوح أعمارهم بين ٦ أشهر وما فوق. لأن فوائد مونتاس قد لا تفوق مخاطر الأعراض النفسية العصبية في المرضى الذين يعانون من التهاب الأنف التحسسي</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب حجز مونتاس فقط لعلاج التهاب الأنف التحسسي في المرضى الذين لا يتم علاجهم بفعالية أو لا يمكنهم تحمل أدوية الحساسية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">طبيبك سوف يحدد الكيفية التي ينبغي بها أن تستخدم مونتاس اعتمادا على شدة الأعراض وحالة الربو لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو الربو؟</strong></p><p dir="RTL">الربو هو مرض طويل الأجل.</p><p dir="RTL">الربو يشمل على ما يلي :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس بسبب ضيق الشعب الهوائية. هذا الضيق في الشعب الهوائية يزداد سوءا ويتحسن استجابة لظروف مختلفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجارى التنفس الحساسة التي تتفاعل مع عدة أشياء كثيرة، مثل دخان السجائر، غبار الطلع، والهواء البارد، أو ممارسة الرياضة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (التهاب) في بطانة الشعب الهوائية.</p><p dir="RTL">أعراض الربو ما يلي: السعال، وصفير عند التنفس ، وضيق في الصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>ما هي الحساسية الموسمية؟</strong></p><p dir="RTL">الحساسية الموسمية (المعروف أيضا باسم حمى القش أو حساسية الأنف الموسمية) هي رد فعل تحسسي غالبا ما يسببه حبوب اللقاح التي يحملها الجو من الأعشاب والأشجار والأعشاب الضارة. أعراض الحساسية الموسمية قد تشمل عادة: الاحساس بالخنق، سيلان الأنف، حكة الأنف؛ العطس؛، تورم مائي، أحمرار، حكة في العيون.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك عن أي مشاكل طبية أو حساسية لديك الآن أو كانت لديك سابقا.</p><p dir="RTL"><strong>لا تتناول مونتاس إذا كنت </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية (تفاعل فرط الحساسية) لمونتيلوكاست أو أي من المكونات الأخرى للمونتاس (انظر 6. مزيد من المعلومات).&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلاني قبل تناول مونتاس</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا الربو أو التنفس يسوء، أخبر طبيبك فورا.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مونتاس عن طريق الفم لعلاج ليس المقصود به علاج نوبات الربو الحادة. اذا حصلت نوبة ربو، اتبع تعليمات التي أعطاك الطبيب دائما استخدم باقي الادوية المستنشقة للانقاذ من نوبات الربو معك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;من المهم أن كنت أنت أو طفلك أخذ جميع أدوية الربو الموصوفة من قبل الطبيب. لا ينبغي أن تستخدم مونتاس بديلا عن أدوية الربو الأخرى التي تم وصفها من قبل طبيبك .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ينبغي لأي مريض بالربو أن يدرك إذا تطورت لديه خليط من الاعراض مثل اعراض الانفلونزا و احساس وخز الإبر والدبابيس أو خدر في الذراعين أو الساقين، تفاقم الأعراض الرئوية، و / أو الطفح الجلدي، ويجب عليك استشارة طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يجب أن لا تتناول حمض أسيتيل الساليسيليك (الأسبرين) أو الأدوية المضادة للالتهابات (المعروف أيضا باسم العقاقير المضادة للالتهابات غير الستيرويدية أو مضادات الالتهاب غير الستيروئيدية) اذ انها قد تجعل الربو لديك أكثر سوءا.</p><p dir="RTL">يجب أن يكون المرضى على دراية بأنه تم الإبلاغ عن العديد من الأحداث النفسية العصبية الخطيرة التي قد تتضمن أفكارًا أو أعمالًا انتحارية تم الإبلاغ عنها عند تناول المريض لـمونتيلوكاست</p><p dir="RTL">إذا ظهرت عليك مثل هذه الأعراض أثناء تناول مونتاس ، يجب عليك استشارة طبيبك.</p><p dir="RTL">اسأل المرضى اذا كان لديه &nbsp;تاريخ لمرض نفسي قبل بدء العلاج.</p><p dir="RTL">ضع في اعتبارك مخاطر وفوائد مونتيلوكاست عندما تقرر وصف أو مواصلة المرضى على الدواء.</p><p dir="RTL">راقب جميع المرضى الذين عولجوا بمونتيلوكاست بحثًا عن أعراض عصبية نفسية. حدثت الأعراض في المرضى الذين يعانون من مرض نفسي أو الذين لا يعانون من مرض نفسي.</p><p dir="RTL">نصح المرضى وأولياء الأمور / مقدمي الرعاية بأنه يجب على المريض التوقف عن تناول مونتيلوكاست والاتصال بأخصائي الرعاية الصحية على الفور في حالة حدوث تغيرات سلوكية أو أعراض عصبية نفسية جديدة أو أفكار انتحارية أو سلوكية.</p><p dir="RTL">حدثت معظم الحالات المبلغ عنها لأحداث نفسية عصبية أثناء علاج المونتيلوكاسترايت ، لكن بعضها حدث بعد التوقف عن استخدامه.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تعطي هذه الأدوية للأطفال أقل من 15 سنة من العمر.</p><p dir="RTL">هناك أشكال مختلفة من هذا الدواء متوفر للمرضى الأطفال تحت سن 18 سنة من العمر على أساس الفئة العمرية.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل مونتاس ، أو قد يؤثر مونتاس في طريقة عمل الأدوية أخرى.</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أدوية أخرى، بما في ذلك التي حصلت عليها من دون وصفة طبية.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول الأدوية التالية قبل البدء مونتاس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينوباربيتال (التي تستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين (المستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريفامبيسين (المستخدم في علاج السل والأمراض المعدية الأخرى بعض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جمفبروزيل (التي تستخدم لعلاج مستويات الدهون عالية في البلازما)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول مونتاس مع الطعام والشراب</strong></p><p dir="RTL">يمكن أن يؤخذ مونتاس 10 ملجم مع أو بدون الطعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، أو تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل ،اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول مونتاس.</p><p dir="RTL"><em>الاستخدام في الحمل</em></p><p dir="RTL">طبيبك سوف يقيم ما إذا كان يمكنك أن تتناولي مونتاس خلال هذه الفترة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاستخدام في الرضاعة الطبيعية</p><p dir="RTL">ومن غير المعروف إذا ما&nbsp; كان مونتاس يظهر في حليب الثدي. يجب استشارة الطبيب قبل تناول مونتاس إذا كنت مرضعة&nbsp; طبيعيا أو تنوين&nbsp; الإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآليات</strong></p><p dir="RTL">مونتاس ليس من المتوقع أن يؤثر على القدرة على قيادة السيارة أو تشغيل الآلات. ومع ذلك، الردود الفردية على الأدوية تختلف. بعض الآثار الجانبية معينة (مثل الدوخة والنعاس) التي تم الإبلاغ عنها في حالات نادرة جدا مع مونتاس تؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات مونتاس</strong></p><p dir="RTL">أقراص مونتاس 10 ملجم المغلفة بفيلم تحتوي على اللاكتوز. إذا قيل لك من قبل الطبيب أن لديك التعصب لبعض السكريات، اتصل بطبيبك قبل اتخاذ هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تناول هذا الدواء دائمًا تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك&nbsp; أو الصيدلي إذا لم تكن متأكدًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول حبة واحدة فقط من مونتاس مرة واحدة يوميا على النحو الذي يحدده الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تناوله حتى عندما يكون لديك أي أعراض أو لديك نوبة الربو الحادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يؤخذ عن طريق الفم</p><p dir="RTL"><strong>للبالغين 15 عاما من العمر وكبار السن</strong><strong>:</strong></p><p dir="RTL">يتعين اخذ حبة واحدة 10 ملجم يوميا في المساء. يمكن أن تؤخذ مونتاس 10 ملجم مع أو بدون الطعام.</p><p dir="RTL">إذا كنت تأخذ مونتاس، أن تتأكد من أن أنك لا تأخذ أي من المنتجات الأخرى التي تحتوي على نفس العنصر النشط، مونتيلوكاست.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>إذا تناولت مونتاس &nbsp;أكثر من اللازم من </strong></p><p dir="RTL">اتصل بطبيبك على الفور للحصول على المشورة.</p><p dir="RTL">لم تكن هناك آثار جانبية ذكرت في معظم تقارير الجرعة الزائدة. معظم الأعراض الشائعة التي تحدث مع الجرعة الزائدة ذكرت في البالغين والأطفال هي&nbsp; آلام في البطن، والنعاس، والعطش والصداع والقيء، وفرط النشاط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول مونتاس</strong></p><p dir="RTL">حاول تناول مونتاس على&nbsp; النحو المنصوص عليه. ومع ذلك، إذا كنت فوت جرعة واستئناف الجدول الزمني المعتاد فقط من قرص واحد مرة واحدة يوميا.</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>إذا توقفت عن تناول مونتاس</strong></p><p dir="RTL">مونتاس يمكن يعالج الربو الخاص بك فقط إذا قمت بتناوله بصفه مستمرة.</p><p dir="RTL">من المهم الاستمرار في تناول مونتاس بطول الفترة التي وصفها الطبيب. وسوف يساعد في السيطرة على الربو الخاص بك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لمونتاس أن يتسبب في آثار جانبية ، وإن لم يكن الجميع يحصل عليها.</p><p dir="RTL">في الدراسات السريرية مع أقراص مونتاس 10 ملجم المغلفة بفيلم ، والآثار الجانبية الأكثر شيوعا (وقعت في ما لا يقل عن 1 من 100 مريض وتم علاج أقل من 1 من 10 مرضى) يعتقد أن لهما صلة مونتاس هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الصداع</p><p dir="RTL">&nbsp;</p><p dir="RTL">وكانت هذه الاعراض عادة ما تكون خفيفة وقعت &nbsp;بمعدل أكثر في المرضى الذين يتناولون مونتاس من الذين يتناولون العلاج الوهمي البلاسيبو (الحبوب التي لا تحتوي على الدواء).</p><p dir="RTL">الاثار الجانبية المحتملة الأكثر تكرارا يتم تعريفها كما هو مذكور أدناه باستخدام المصلحات التالية:</p><p dir="RTL">شائعة جدا (حدثت&nbsp; في 1 من كل 10 مستخدم )</p><p dir="RTL">الشائعة (حدتث في 1 إلى 10 من كل&nbsp; 100 مستخدم )</p><p dir="RTL">الغير شائعة ( حدثت في 1 إلى 10 من كل&nbsp; 1000 مستخدم )</p><p dir="RTL">النادرة (حدثت في 1 إلى 10 من كل&nbsp; 10000 مستخدم )</p><p dir="RTL">النادرة جدا (حدثت في أقل من 1 مستخدم من كل 10000 مستخدم)</p><p dir="RTL">الغير معروفة: لا يمكن تقدير المعدل من البيانات المتاحة</p><p dir="RTL"><strong>آثار جانبية خطيرة</strong></p><p dir="RTL"><strong>تحدث مع طبيبك على الفور</strong> إذا لاحظت أيًا من الآثار الجانبية التالية ، والتي قد تكون خطيرة ، والتي قد تحتاج إلى علاج طبي عاجل</p><p dir="RTL"><strong>الغير شائعة</strong> (تؤثر على 1 إلى 10 مستخدمين في 1000)</p><ul><li dir="RTL">ردود فعل تحسسية بما في ذلك تورم الوجه والشفاه واللسان و / أو الحلق والتي قد تسبب صعوبة في التنفس أو البلع</li><li dir="RTL">التغيرات المتعلقة بالسلوك والمزاج: الانفعالات بما في ذلك السلوك العدواني أو العداء و القلق والاكتئاب</li><li dir="RTL">التشنجات</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة</strong>: قد تؤثر ما يلي على ما يصل إلى 1 من كل 1000 شخص</p><ul><li dir="RTL">زيادة القابلية النزيف</li><li dir="RTL">ارتعاش</li><li dir="RTL">خفقان</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة جدًا</strong>: قد يؤثر ما يلي على ما يصل إلى 1 من بين 10000 شخص</p><ul><li dir="RTL">مجموعة من الأعراض تشبه أعراض &nbsp;مرض الإنفلونزا ،الاحساس &nbsp;بالوخز أو خدر في الذراعين والساقين ، وتفاقم الأعراض الرئوية و / أو الطفح الجلدي (متلازمة شورج ستراوس) (انظر القسم 2)</li><li dir="RTL">انخفاض عدد الصفائح الدموية</li><li dir="RTL">التغيرات المتعلقة بالسلوك والمزاج: الهلوسة ، الارتباك ، الأفكار أو اعمال انتحارية</li><li dir="RTL">تورم (التهاب) الرئتين</li><li dir="RTL">تفاعلات جلدية شديدة (حمامي متعددة الأشكال) قد تحدث دون سابق إنذار</li><li dir="RTL">التهاب الكبد (التهاب الكبد)</li></ul><p dir="RTL"><strong>آثار جانبية أخرى أثناء وجود الدواء في السوق</strong></p><p dir="RTL"><strong>الشائعة جدًا</strong>: ما يلي قد تؤثر على أكثر من 1 من كل 10 أشخاص</p><ul><li dir="RTL">عدوى الجهاز التنفسي العلوي</li></ul><p dir="RTL"><strong>الشائعة</strong>: ما يلي قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص</p><ul><li dir="RTL">الإسهال والغثيان والقيء</li><li dir="RTL">طفح جلدي</li><li dir="RTL">حمى</li><li dir="RTL">ارتفاع في إنزيمات الكبد</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الغير شائعة</strong>: ما يلي قد يؤثر على ما يصل إلى 1 من كل 100 شخص</p><ul><li dir="RTL">التغييرات المتعلقة بالسلوك والمزاج: الاحلام الغير طبيعية ، بما في ذلك الكوابيس ، صعوبة النوم ، المشي اثناء النوم ، تهيج ، شعور بالقلق ، التَّمَلْمُل</li><li dir="RTL">دوار ، نعاس ، الاحساس بالوخز / تنميل</li><li dir="RTL">نزيف في الأنف</li><li dir="RTL">جفاف الفم وعسر الهضم</li><li dir="RTL">كدمات ، حكة ، شرى</li><li dir="RTL">آلام في المفاصل أو العضلات ، وتشنجات عضلية</li><li dir="RTL">التبول اللاإرادي لدى الأطفال</li><li dir="RTL">الضعف / التعب ، الشعور بالإعياء ، التورم</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة</strong>: قد يؤثر ما يلي على ما يصل إلى 1 من كل 1000 شخص</p><ul><li dir="RTL">التغيرات السلوكية والمزاجية: اضطراب الانتباه ، ضعف الذاكرة ،حركات العضلات غير المنضبط</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة جدًا</strong>: قد يؤثر ما يلي على ما يصل إلى 1 من بين 10000 شخص</p><ul><li dir="RTL">كتل حمراء طرية تحت الجلد ، أكثر شيوعًا على السيقان (حمامي عقيدي)</li><li dir="RTL">التغيرات المتعلقة بالسلوك والمزاج: أعراض الوسواس القهري ، تَأْتَأَةٌ نَفْسِيَّةُ المَنْشَأ (التلعثم)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحفظ بعيدا عن متناول وبصرالأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لا تستخدم هذا الدواء بعد تاريخ الاتنهاء . تاريخ انتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&nbsp; درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير لحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة النشطة: هي مونتيلوكاست. كل قرص يحتوي على مونتيلوكاست الصوديوم والتي تطابق 10 ملجم من مونتيلوكاست.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: مونوهيدرات اللاكتوز، ميكروكرستالين السليلوز ، كروسكارملليوز الصوديوم ، الإيثانول، هيدروكسيبروبيلسيليلوز ، ستيرات المغنيسيوم،)اوبدري &nbsp;TAN AMB (80W27179 والمياه النقية.</p><p dir="RTL">اوبدري &nbsp;TAN AMB (80W27179) مزيج يتألف من البولي فينيل الكحول وثاني أكسيد التيتانيوم (E171)، التلك، وأكسيد الحديد الأصفر (&Epsilon;172)، الليسيثين،صمغ الزنتان ، أكسيد الحديد الأحمر (&Epsilon;172) وأكسيد الحديد الأسود (&Epsilon;172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو شكل مونتاس ومحتويات العبوة</strong></p><p dir="RTL">أقراص مونتاس 10 ملجم المغلفة بفيلم هي بيج في اللون، أقراص ثنائية التحدب، مع &quot;NM10&quot; تنقش على جانب واحد وسهل من جهة أخرى.</p><p dir="RTL">صفائح رقيقة من الألمنيوم / الألومنيوم (OPA / AL / PVC) عبوة من شرائط من 28 قرص (4 &times; 7 )</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة وصاحبة حقوق التسويق </strong></p><p dir="RTL">الشركة العمانية لمستحضرات الصيدلة ش.م.م</p><p dir="RTL">&nbsp;صلالة، سلطنة عمان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ إصدار هذه النشرة: يوليو  2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Montas 10mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains:
Montelukast Sodium IHS10.40mg
equivalent to Montelukast 10mg.
For excipients refer Section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
‘Beige,Round biconvex tablets with“MN10”debossed on one side and plain on the other side.”
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Montas tablets is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montas tablets is indicated in asthma, Montas tablets can also provide symptomatic relief of seasonal allergic rhinitis.</p><p style="text-align:justify">Montas tablets are also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.</p><p>Allergic Rhinitis</p><p style="text-align:justify">MONTAS is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of MONTAS may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see section 4.4], reserve use for patients who have an inadequate response or intolerance to alternative therapies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">1.1&nbsp; Posology</p><p style="text-align:justify">The recommended dose for adults and adolescents 15 years of age and older with asthma, or with asthma and concomitant seasonal allergic rhinitis is one 10 mg tablet daily to be taken in the evening.</p><p style="text-align:justify"><u>General recommendations</u></p><p style="text-align:justify">The therapeutic effect of Montas tablets on parameters of asthma control occurs within one day. Montas tablets may be taken with or without food. Patients should be advised to continue taking Montas tablets even if their asthma is under control, as well as during periods of worsening asthma. Montas tablets should not be used concomitantly with other products containing the same active ingredient, Montelukast.</p><p style="text-align:justify">No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p style="text-align:justify"><u>Therapy with Montas tablets in relation to other treatments for asthma</u>: Montas tablets can be added to a patient&#39;s existing treatment regimen.</p><p style="text-align:justify"><em>Inhaled corticosteroids: </em>Treatment with Montas tablets can be used as add-on therapy in patients when inhaled corticosteroids plus &ldquo;as needed&rdquo; short acting &beta;-agonists provides inadequate clinical control. Montas tablets should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p style="text-align:justify"><em>Paediatric population</em>: Do not give Montas tablets 10 mg film-coated tablets to children less than 15 years of age. The safety and efficacy of Montas tablets 10 mg film-coated tablets in children less than 15 years has not been established.</p><p style="text-align:justify">5 mg chewable tablets are available for paediatric patients 6 to 14 years of age. 4 mg chewable tablets are available for paediatric patients 2 to 5 years of age. 4 mg granules are available for paediatric patients 6 months to 5 years of age.</p><p style="text-align:justify">&nbsp;</p><p><strong>Method of administration</strong></p><p>Oral use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p style="text-align:justify">Montelukast should not be substituted abruptly for inhaled or oral corticosteroids.</p><p style="text-align:justify">There are no data demonstrating that oral corticosteroids can be reduced when Montelukast is given concomitantly.</p><p style="text-align:justify">In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p style="text-align:justify">Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p style="text-align:justify">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p style="text-align:justify">Neuropsychiatric events have been reported in adults, adolescents, and children taking Montas tablets (see section 4.8). Patients and physicians should be alert for neuropsychiatric events. Patients and/or caregivers should be instructed to notify their physician if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Montas tablets if such events occur.</p><p style="text-align:justify"><strong>Neuropsychiatric Events</strong></p><p style="text-align:justify">Serious neuropsychiatric (NP) events have been reported with use of MONTAS. These post marketing reports have been highly variable and included, but were not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thoughts and behavior (including suicide), tic, and tremor. NP events have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder. NP events have been reported mostly during MONTAS treatment, but some were reported after MONTAS discontinuation. Animal studies showed that montelukast distributes into the brain in rats; however, the mechanisms underlying MONTAS-associated NP events are currently not well understood. Based upon the available data, it is difficult to identify risk factors for or quantify the risk of NP events with MONTAS use.</p><p style="text-align:justify">Because of the risk of NP events, the benefits of MONTAS may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of MONTAS for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see section 4.1], in patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing MONTAS.</p><p style="text-align:justify">Discuss the benefits and risks of MONTAS use with patients and caregivers when prescribing MONTAS. Advise patients and/or caregivers to be alert for changes in behavior or for new NP symptoms when taking MONTAS. If changes in behavior are observed, or if new symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue MONTAS and contact a healthcare provider immediately. In many cases, symptoms resolved after stopping MONTAS therapy; however, in some cases symptoms persisted after discontinuation of MONTAS. Therefore, continue to monitor and provide supportive care until symptoms resolve. Re-evaluate the benefits and risks of restarting treatment with MONTAS if such events occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products:</p><p style="text-align:justify">Theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin</p><p style="text-align:justify">The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p style="text-align:justify"><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).</p><p style="text-align:justify"><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p style="text-align:justify">Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Pregnancy</u></p><p style="text-align:justify">Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p style="text-align:justify">Available data from published prospective and retrospective cohort studies with montelukast use in pregnant women evaluating major birth defects have not established a drug-associated risk. Available studies have methodologic limitations, including small sample size, in some cases retrospective data collection, and inconsistent comparator groups.Montas tablets may be used during pregnancy only if it is considered to be clearly essential.</p><p style="text-align:justify"><u>Breast-feeding</u></p><p style="text-align:justify">Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p style="text-align:justify">Montas tablets may be used in breast-feeding only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montas tablets has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Montelukast has been evaluated in clinical studies as follows:</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 mg film-coated tablets in approximately 4,000 adult and adolescent asthmatic patients 15 years of age and older.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 mg film-coated tablets in approximately 400 adult and adolescent asthmatic patients with seasonal allergic rhinitis 15 years of age and older.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 mg chewable tablets in approximately 1,750 paediatric asthmatic patients 6 to 14 years of age.</p><p style="text-align:justify">The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in asthmatic patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Adult and Adolescent Patients 15 years and older</strong></p><p style="text-align:justify"><strong>(two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p style="text-align:justify"><strong>Paediatric Patients 6 to 14 years old</strong></p><p style="text-align:justify"><strong>(one 8-week study; n=201) (two 56-week studies; n=615)</strong></p></td></tr></tbody></table><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">headache</p></td><td style="vertical-align:top"><p style="text-align:justify">headache</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:justify"><strong>Gastro-intestinal disorders</strong></p></td><td style="vertical-align:top"><p style="text-align:justify">abdominal pain</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td></tr></tbody></table><p style="text-align:justify">With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Post Marketing Experience:</p><p style="text-align:justify">Psychiatric disorders: including, but not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive- compulsive symptoms, restlessness, somnambulism, suicidal thinking and behavior (including suicide), tic, and tremor [see Boxed Warning, Warnings and Precautions].</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Tabulated list of Adverse Reactions</u></p><p style="text-align:justify">Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0" style="width:743px"><tbody><tr><td style="vertical-align:top; width:159px"><p style="text-align:justify"><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:422px"><p style="text-align:justify"><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify"><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top; width:159px"><p style="text-align:justify">Infections and infestations</p></td><td style="vertical-align:top; width:422px"><p style="text-align:justify">upper respiratory infection<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Very Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:159px"><p style="text-align:justify">Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:422px"><p style="text-align:justify">increased bleeding tendency</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Rare</p></td></tr><tr><td style="vertical-align:top; width:422px"><p style="text-align:justify">thrombocytopenia</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:159px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Immune system disorders</p></td><td style="vertical-align:top; width:422px"><p style="text-align:justify">hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:422px"><p style="text-align:justify">hepatic eosinophilic infiltration</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:159px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Psychiatric disorders</p></td><td style="vertical-align:top; width:422px"><p style="text-align:justify">dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor<sup>&sect;</sup>)</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:422px"><p style="text-align:justify">disturbance in attention, memory impairment, tic</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Rare</p></td></tr><tr><td style="vertical-align:top; width:422px"><p style="text-align:justify">hallucinations, disorientation, suicidal</p></td><td style="vertical-align:top; width:161px"><p style="text-align:justify">Very Rare</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:745px"><tbody><tr><td style="vertical-align:top; width:158px"><p style="text-align:justify">&nbsp;</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">thinking and behaviour (suicidality), obsessive-compulsive symptoms, dysphemia</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:158px"><p style="text-align:justify">Nervous system disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:158px"><p style="text-align:justify">Cardiac disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">palpitations</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:158px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">epistaxis</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Very Rare</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">pulmonary eosinophilia</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:158px"><p style="text-align:justify">Gastro-intestinal disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">diarrhoea<sup>&Dagger;</sup>, nausea<sup>&Dagger;</sup>, vomiting<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">dry mouth, dyspepsia</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:158px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Hepatobiliary disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:158px"><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">rash<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">bruising, urticaria, pruritus</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">angiooedema</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Rare</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Very Rare</p></td></tr><tr><td style="vertical-align:top; width:158px"><p style="text-align:justify">Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:158px"><p style="text-align:justify">Renal and urinary disorders</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">enuresis in children</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:158px"><p style="text-align:justify">General disorders and administration site conditions</p></td><td style="vertical-align:top; width:423px"><p style="text-align:justify">pyrexia<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:423px"><p style="text-align:justify">asthenia/fatigue, malaise, oedema</p></td><td style="vertical-align:top; width:163px"><p style="text-align:justify">Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:742px"><p style="text-align:justify">*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p style="text-align:justify"><sup>&dagger;</sup>This adverse experience, reported as Very Common in the patients who received</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span style='font-size:
10.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><span style='mso-element:field-begin;mso-field-lock:
yes'></span><span style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='width:454.6pt;
 height:83.05pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokecolor="#7a7a7a"
 strokeweight=".71pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:1.15pt;margin-right:26.0pt;
    margin-bottom:0in;margin-left:1.2pt;margin-bottom:.0001pt;line-height:115%'>montelukast,<span
    style='letter-spacing:-.05pt'> </span>was<span style='letter-spacing:-.05pt'>
    </span>also<span style='letter-spacing:-.05pt'> </span>reported<span
    style='letter-spacing:-.05pt'> </span>as<span style='letter-spacing:-.05pt'>
    </span>Very<span style='letter-spacing:-.3pt'> </span>Common in<span
    style='letter-spacing:-.05pt'> </span>the<span style='letter-spacing:-.1pt'>
    </span>patients<span style='letter-spacing:-.05pt'> </span>who<span
    style='letter-spacing:-.05pt'> </span>received<span style='letter-spacing:
    -.05pt'> </span>placebo<span style='letter-spacing:-.05pt'> </span>in<span
    style='letter-spacing:-2.85pt'> </span>clinical<span style='letter-spacing:
    -.05pt'> </span>trials.<o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:0in;margin-right:1.15pt;margin-bottom:
    0in;margin-left:1.2pt;margin-bottom:.0001pt;line-height:115%'><sup>‡</sup>This
    adverse experience, reported as Common in the patients who received
    montelukast, was<span style='letter-spacing:-2.85pt'> </span>also<span
    style='letter-spacing:-.05pt'> </span>reported<span style='letter-spacing:
    .05pt'> </span>as Common<span style='letter-spacing:-.05pt'> </span>in the<span
    style='letter-spacing:-.1pt'> </span>patients who<span style='letter-spacing:
    -.05pt'> </span>received placebo<span style='letter-spacing:-.05pt'> </span>in
    clinical<span style='letter-spacing:.05pt'> </span>trials.<o:p></o:p></p>
    <p class=MsoBodyText style='margin-left:1.2pt;line-height:13.75pt;
    mso-line-height-rule:exactly'><sup>§</sup><span style='letter-spacing:-.75pt'>
    </span>Frequency<span style='letter-spacing:.05pt'> </span>Category:<span
    style='letter-spacing:.25pt'> </span>Rare<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="612" height="117" alt="Text Box: montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.
‡This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.
§ Frequency Category: Rare
" src="file:///C:\Users\Nidhi\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:454.6pt;height:83.05pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p style="text-align:justify">There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p style="text-align:justify"><u>Symptoms of overdose</u></p><p style="text-align:justify">The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p style="text-align:justify"><u>Management of overdose</u></p><p style="text-align:justify">No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemodialysis.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pharmacotherapeutic group: </strong>Leukotriene receptor antagonist</p><p style="text-align:justify"><strong>ATC-code: </strong>R03D C03</p><p style="text-align:justify"><u>Mechanism of action</u></p><p style="text-align:justify">The cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT<sub>1</sub>) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.</p><p style="text-align:justify"><u>Pharmacodynamic effects</u></p><p style="text-align:justify">Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT<sub>1</sub> receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD<sub>4</sub> at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp; montelukast&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhibited&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; both&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; early-&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum) and in peripheral blood while improving clinical asthma control.</p><p style="text-align:justify"><u>Clinical efficacy and safety</u></p><p style="text-align:justify">In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV<sub>1</sub> (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p style="text-align:justify">Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV<sub>1</sub>: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV<sub>1</sub>: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV<sub>1</sub> of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p style="text-align:justify">A clinical study was conducted to evaluate montelukast for the symptomatic treatment of seasonal allergic rhinitis in adult and adolescent asthmatic patients 15 years of age and older with concomitant seasonal allergic rhinitis. In this study, montelukast 10 mg tablets administered once daily demonstrated a statistically significant improvement in the Daily Rhinitis Symptoms score, compared with placebo. The Daily Rhinitis Symptoms score is the average of the Daytime Nasal Symptoms score (mean of nasal congestion, rhinorrhea, sneezing, nasal itching) and the Nighttime Symptoms score (mean of nasal congestion upon awakening, difficulty going to sleep, and nighttime awakenings scores). Global evaluations of allergic rhinitis by patients and physicians were significantly improved, compared with placebo. The evaluation of asthma efficacy was not a primary objective in this study.</p><p style="text-align:justify">In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV<sub>1</sub> 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p style="text-align:justify">Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12- week study in adults (maximal fall in FEV<sub>1</sub> 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV<sub>1</sub> 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients (maximal fall in FEV<sub>1</sub> 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV<sub>1</sub> 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p style="text-align:justify">In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV<sub>1</sub> 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Absorption</u></p><p style="text-align:justify">Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved 3 hours (T<sub>max</sub>) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C<sub>max</sub> are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p style="text-align:justify">For the 5 mg chewable tablet, the C<sub>max</sub> is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p style="text-align:justify"><u>Distribution</u></p><p style="text-align:justify">Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p style="text-align:justify"><u>Biotransformation</u></p><p style="text-align:justify">Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p style="text-align:justify">Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p style="text-align:justify"><u>Elimination</u></p><p style="text-align:justify">The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p style="text-align:justify"><u>Characteristics in Patients</u></p><p style="text-align:justify">No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p style="text-align:justify">With high doses of montelukast (20- and 60-fold the recommended adult dose), decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastrointestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p style="text-align:justify">No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m<sup>2</sup> and 30,000 mg/m<sup>2</sup> in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p style="text-align:justify">Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p style="text-align:justify">Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, Microcrystalline cellulose, Croscarmellose sodium, Ethanol, Hydroxypropylcellulose, Magnesium stearate,</p><p>Opadry AMB TAN (80W27179),</p><p>Purified water</p><p><em>Opadry AMB TAN (80W27179) blend Contains</em>:</p><p>Polyvinyl alcohol, Titanium dioxide (E171), Talc,</p><p>Iron oxide yellow (&Epsilon;172),</p><p>Lecithin, Xanthan gum,</p><p>Iron Oxide red (&Epsilon;172), Iron oxide black (&Epsilon;172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Keep out of the reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium Laminate Foil (OPA/AL/PVC) blister pack of 28 tablets (4 &times; 7&rsquo;s)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oman Pharmaceutical Products Co. L.L.C. Plot No 101, Raysut Industrial Estate, Salalah, Sultanate of Oman
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>